(12) **Translation of European patent specification**

(11) **NO/EP 3302499 B1**

NORWAY

(19) NO

(51) Int Cl.

A61K 31/7052 (2006.01)
A61K 31/7084 (2006.01)
A61K 31/7088 (2006.01)
A61P 43/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.06.19
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.03.15
(86)	European Application Nr.	16728892.7
(86)	European Filing Date	2016.06.03
(87)	The European Application's Publication Date	2018.04.11
(30)	Priority	2015.06.05, EP, 15170825
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca, Passeig Vall d'Hebrón, 119-129, 08035 Barcelona, Spania Centro de Investigación Biomédica en Red (CIBER), Instituto de Salud Carlos III Pabellón 11. planta baja C/Monforte de Lemos 3-5, 28029 Madrid, Spania
(72)	Inventor	MARTÍ SEVES, Ramon, C. Martínez de la Rosa 4 4º 1ª, 08012 Barcelona, Spania GONZÁLEZ VIOQUE, Emiliano, C. Maria Barrientos 4 Portal D 1º 2ª, 28021 Madrid, Spania BLÁZQUEZ BERMEJO, Cora, C. Miguel Alduncin 37 2º A, 20100 Errenteria, Spania TORRES TORRONTERAS, Javier, Passatge Clara Campoamor 3-9 2º 4ª, 08820 El Prat De Llobregat, Spania CABRERA PÉREZ, Raquel, Avinguda Maria Girona 37 1º, 08830 Sant Boi De Llobregat, Spania CÁMARA NAVARRO, Yolanda, Rambla Fabra i Puig 29-31 1º 4ª, 08030 Barcelona, Spania
(74)	Agent or Attorney	AWA NORWAY AS, Hoffsveien 1A, 0275 OSLO, Norge

(54) Title **TREATMENT OF MITOCHONDRIAL DISEASES**

(56) References Cited:

CN-A- 104 524 546
WO-A1-00/50043
EL-HATTAB AYMAN W ET AL: "Mitochondrial DNA Depletion Syndromes: Review and Updates of Genetic Basis, Manifestations, and Therapeutic Options", NEUROTHERAPEUTICS, ELSEVIER INC, US, vol. 10, no. 2, 6 February 2013 (2013-02-06), pages 186-198, XP035352266, ISSN: 1933-7213, DOI: 10.1007/S13311-013-0177-6 [retrieved on 2013-02-06]
S. KRISHNAN ET AL: "Transgene Expression of Drosophila melanogaster Nucleoside Kinase Reverses Mitochondrial Thymidine Kinase 2 Deficiency", JOURNAL OF BIOLOGICAL

CHEMISTRY, vol. 288, no. 7, 15 February 2013 (2013-02-15), pages 5072-5079, XP055228429, US ISSN: 0021-9258, DOI: 10.1074/jbc.M112.437152
Walker UA, Venhoff N.: "Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity.", pubmed , 2005, XP002751217, Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pubmed/161 52713 [retrieved on 2015-01-13]
S. BULST ET AL: "In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromes", HUMAN MOLECULAR GENETICS, vol. 18, no. 9, 1 May 2009 (2009-05-01), pages 1590-1599, XP055228477, gb ISSN: 0964-6906, DOI: 10.1093/hmg/ddp074
RUSSELL P. SANETO ET AL: "Alpers-Huttenlocher Syndrome", PEDIATRIC NEUROLOGY., vol. 48, no. 3, 1 March 2013 (2013-03-01), pages 167-178, XP055228448, NL ISSN: 0887-8994, DOI: 10.1016/j.pediatrneurol.2012.09.014
KEIKO SAITO ET AL: "Pyruvate therapy for mitochondrial DNA depletion syndrome", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - GENERAL SUBJECTS, vol. 1820, no. 5, 1 May 2012 (2012-05-01), pages 632-636, XP055228134, AMSTERDAM, NL ISSN: 0304-4165, DOI: 10.1016/j.bbagen.2011.08.006
Y. CAMARA ET AL: "Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndrome", HUMAN MOLECULAR GENETICS, vol. 23, no. 9, 1 May 2014 (2014-05-01), pages 2459-2467, XP055228156, gb ISSN: 0964-6906, DOI: 10.1093/hmg/ddt641

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. En sammensetning omfattende deoksyadenosin, deoksyguanosin, deoksycytidin, og deoksytymidin til anvendelse for å behandle et mitokondrielt DNA-deplesjons- og/eller delesjonssyndrom, der syndromet skyldes en defekt i DNA polymerase subenheten gamma-1 (POLG1)-protein.

2. Sammensetningen til anvendelse ifølge krav 1, der det mitokondrielle DNA deplesjons- og delesjonssyndromet er forårsaket av en defekt i den mitokondrielle replikasjonsveien, nevnte defekt skyldes en eller flere av følgende mutasjoner i POLG1-proteinet: R309C, W748S, V1177L, G848S, E1143, og E1143G, posisjonene er referert til med hensyn til SEQ ID NO:1.

3. Sammensetningen til anvendelse ifølge et hvilket som helst av kravene 1 eller 2, som ikke inneholder noe annet ytterligere nukleosid.

4. Sammensetningen til anvendelse ifølge et hvilket som helst av de foregående kravene, der sammensetningen videre omfatter en eller flere farmasøytisk akseptable inhibitorer av nukleosid-nedbrytning.

5. Sammensetningen til anvendelse ifølge krav 4, der den farmasøytisk akseptable inhibitoren er en inhibitor av deoksyadenosin-nedbrytning.

6. Sammensetningen til anvendelse ifølge krav 5, der inhibitoren er erytro-9-(2-hydroksy-3-nonyl)adenin (EHNA).